The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The "Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis" Registry

: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA monotherapy for the reduction in ischemic major adverse cardiovascular events (MACEs, i.e., cardiovascular death, stroke, or m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical medicine 2024-04, Vol.13 (7), p.1956
Hauptverfasser:	Breitenstein, Alexander, Gay, Alain, Vogtländer, Kai, Fox, Keith A A, Steffel, Jan
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Aspirin Atherosclerosis Cardiovascular disease Clinical outcomes Clinical trials Diabetes Disease prevention Dosage and administration Drug therapy Drug therapy, Combination Enrollments Heart attacks Heart failure Ischemia Patient outcomes Patients Rivaroxaban Statistical analysis Statistics Stroke Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!